PRESS RELEASE

CARMAT announces updates in its governance

- **Appointment of Mr. Pierre Bastid as Chairman of the Board of Directors to succeed Mr. Alexandre Conroy, who has resigned for personal reasons**
- **Retirement of Mr. André Muller, independent director, following his appointment as Chief Executive Officer of Idorsia**

Paris, June 25, 2024 – 7:00 am (CEST)

CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "**Company**" or "**CARMAT**"), announces the appointment of Mr. Pierre Bastid, Director, as Chairman of the Board of CARMAT, replacing Mr. Alexandre Conroy, who has resigned for personal reasons; and the retirement of Mr. André Muller, Director, following his appointment as CEO of Idorsia.

A seasoned industrialist and entrepreneur, Mr. Pierre Bastid knows CARMAT very well, having served on its Board as a director since 2018. He is also one of the Company's main shareholders via the LOHAS and Les Bastidons entities, which he controls, and which together hold 13.5% of the Company's share capital. Since taking a stake in CARMAT back in 2016, Mr. Pierre Bastid has participated in each of the capital increases carried out by the Company.

Following these changes, CARMAT's Board of Directors, now chaired by Pierre Bastid, consists of 10 members, including 5 independent.

Pierre Bastid, Chairman of CARMAT's Board of Directors, comments: *"I'm delighted to take over as Chairman of the Board of Directors of CARMAT, whose Aeson® artificial heart is absolutely unique and carries immense potential. The entire Board and I are fully mobilized alongside the CARMAT teams, and determined to pursue and accelerate the Company's commercial development over the coming months. We are all driven by a common goal: bring a solution to the ever-increasing number of patients suffering from advanced biventricular heart failure."*

Stéphane Piat, Chief Executive Officer of CARMAT, concludes: *"I would like to thank Alexandre Conroy for accompanying CARMAT during a particularly intense period for the Company, as well as André Muller for giving us the opportunity to benefit from his experience and advice for over 4 years. I am also delighted that Pierre Bastid, whose support has been unfailing since 2016, is taking over as Chairman of CARMAT. His many entrepreneurial successes, industrial expertise and commitment will be invaluable assets for our Company."*

***

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).

For more information, please go to www.carmatsa.com and follow us on LinkedIn.

CARMAT
Stéphane Piat
Chief Executive Officer

Pascale d'Arbonneau
Chief Financial Officer
Tel.: +33 1 39 45 64 50
contact@carmatsas.com

Alize RP
Press Relations

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
carmat@alizerp.com

NewCap
Financial Communication
& Investor Relations

Dusan Oresansky
Jérémy Digel
Tel.: +33 1 44 71 94 92
carmat@newcap.eu

Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, nor a solicitation of an order to buy or subscribe to CARMAT shares in any country. This press release may contain forward-looking statements by the company regarding its objectives and prospects. These forward-looking statements are based on the current estimates and anticipations of the company's management and are subject to risk factors and uncertainties such as the company's ability to implement its strategy, the pace of development of CARMAT's production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the company's growth management. The company's objectives mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties.

The Company's material and specific risks are those described in its universal registration document filed with the Autorité des Marchés Financiers (**AMF**) under number D.24-0374. Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-August 2024. Readers' and investors' attention is also drawn to the fact that other risks, unknown or not considered material and specific, may or may not exist.

Aeson® is an active implantable medical device commercially available in the European Union and other countries recognizing CE marking. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant for patients suffering from end-stage biventricular heart failure (INTERMACS classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to undergo a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician manual, patient manual, and alarm booklet) should be carefully read to understand the features of Aeson® and the information necessary for patient selection and proper use (contraindications, precautions, side effects). In the United States, Aeson® is currently exclusively available as part of an Early Feasibility Study approved by the Food & Drug Administration (FDA).